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DISCUSSION
Dr Tej Singh (Sunnyvale, Calif). Good morning. President
Ballard, officers, members and guests of the Western Vascular
Society, I wanted to thank you for the opportunity to discuss Dr.
DeRubertis’ well-written and concise manuscript regarding endo-
vascular outcomes for infrainguinal occlusive disease in women
compared with men.
There is no doubt that the content of the study and the topic
in general causes significant discussion and distress at times in our
vascular surgical community. At every hospital in America, endo-
vascular infrainguinal interventions with new technologies are
happening at a rapidly growing rate, even though the indications,
long-term follow-up and consistent results are still not clear. We all
recognize that rapid growth in these procedures does have some
important clinical advantages in appropriately selected patients.
Selection and patient referral patterns may dictate care in many
centers unfortunately.
Dr DeRubertis and his vascular surgery group have described
in this paper their excellent results and clinical follow-up of a large
number of interventional procedures for lower extremity occlusive
disease in both sexes. As he described in his presentation, women
have equivalent outcomes compared with men even though they
may have more advanced disease, increased task severity, and
unknown hormonal effects. This is promising when we all recog-
nize that some women may have poor surgical options and also
tend to have smaller diameter distal targets making surgical options
difficult technically and with known complications. While it is
promising that women and men have equivalent outcomes based
on the study and without necessary randomized trials, I would
caution the reader and the listener from going out and purchasing
arthrectomy and crossing devices for all patients with chronic limb
ischemia. The primary patency of 40%, secondary patency and 60%,
and limb salvage of 80% at 3 years has been reported in other
experienced centers but may not reflect the results in all clinical
practices which I believe may unfortunately be less.
To stimulate discussion, I have three very important questions
for you.
(1) Approximately 22% of the women in the study had chronic
renal failure or were on dialysis. Can you share any thoughts on
this subgroup of patients and how their results compared with
the rest of the study group? And compared with men with
renal disease? In my experience, these vessels are smaller,
calcified especially in women and tend to fair worse both at
surgery and with endovascular treatment.
(2) For planning purposes, did you use CT angiograms or MRAs
routinely for planning of the case prior to treatment?
(3) Do you have any data describing the balloon and stent diam-
eters used in women compared with men correlating that with
body size and weight? I think it would be interesting to see if
women required smaller or similar size endovascular interven-
tions and still had comparable results.
(4) With the increasing use and understanding of crossing devices,
the surgeons in this study did not use them even though most
of the vessels intervened were the SFA. Why? Were there any
characteristics or selection of these patients that limited the use
of crossing devices? If yes, what were they?
(5) Could you provide us some data in how you handle your
endovascular failures? Do you always reintervene? Do you go
straight to surgery? What are your results with failures?
Finally, and probably the most important question, we must
now start thinking beyond just doing these procedures technically
and reporting our results. Can you speculate how to design the
next important studies and what are the important aspects of those
studies for vascular specialists to help treat our patients?
I thank you for the opportunity to discuss your very well written
paper and eagerly look forward to your responses. Thank you.
DrDeRubertis.Dr. Singh, thank you for your discussion and
your very insightful comments.
First, I would like to a comment on the question of whether
our results are generalizable to the entire population. As vascular
surgeons continue to become increasingly familiar with different
devices and gain advanced endovascular expertise, I think these
results will be obtainable across the board in both community and
academic centers. I think the prerequisite, however, is a true
commitment to undertaking these types of procedures, including
the more complex ones. Part of this commitment involves securing
access to the types of imaging systems required and becoming
familiar with the breadth of devices required for the more difficult
cases.
In response to your question regarding patients with chronic
renal insufficiency, in this series approximately 30% of patients had
an elevated creatinine consistent with chronic renal disease. When
looking at all interventions, the overall rate of worsening renal
dysfunction was just over 2%, and this was equivalent between men
and women. In patients with a baseline creatinine less than 3, the
rate of worsening renal dysfunction was around 13% and the need
for hemodialysis was 0.3%. In patients with a creatinine greater
than 3, these rates were about 40% and 25%, respectively, and only
two of the four patients who required dialysis went on to become
chronically dialysis dependent. Both of these patients had baseline
creatinine of greater than 4 and were therefore already moving
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toward dialysis dependence. All four patients who required dialysis
were intervened upon for limb-threat and had no available conduit.
In terms of the outcomes between men and women, there was
no overall difference between genders in terms of patency and limb
salvage, nor were there any differences between men and women
when stratified by baseline preoperative creatinine level. Further-
more, while other studies have demonstrated differential outcomes
in patients with end-stage renal disease on hemodialysis, we did not
observe such a difference. So to summarize our experience with
patients with chronic renal insufficiency, we believe percutaneous
interventions can be done safely provided the baseline creatinine is
under the 2.5 to 3 range and provided one is conscious of the
contrast usage. The vast majority of interventions can be per-
formed using small volumes of 50% contrast by performing selec-
tive runs on appropriate imaging equipment and avoiding unnec-
essary contrast exposure.
In terms of vessel diameters between men and women, we did
not see a difference in balloon and stent sizes between genders. In
the SFA, the average diameter stent was 5.9 for women and 6.1 for
men, which was statistically equivalent. The differences in stent
sizes were based on location, SFA vs popliteal/tibial.
When determining the point at which your endovascular
approach has failed and the time to perform a surgical bypass has
come, some of the issues to keep in mind include the patient’s
conduit, their overall medical condition or surgical risk, and the
goals of treatment. In a 50-year-old claudicant who has adequate
autologous conduit, one might try a percutaneous intervention
one time and when that fails 6 or 8 months later that patient may
well want the most durable solution to his problem and may elect
at that time for a surgical bypass. On the other hand, in a 90-year-
old patient with recent MI who presents with a nonhealing toe
ulcer, two or three percutaneous interventions, if necessary, may be
appropriate in order to maintain patency long enough to allow the
patient to heal his ulcer and avoid a major operation. I think it
largely depends on what the goals of treatment are. While we hold
no set limits as far as how many interventions one can undergo, we
believe it is of utmost importance to remain conscious of your
surgical bypass targets and avoid any maneuvers that risk injury to
these vessels.
In terms of the next important studies, one relates to the issue
of multiple interventions. We have not yet looked at any cost
analysis aspect of these interventions. I suspect that endovascular
therapy may well be a reasonably sound approach from a financial
standpoint for that first intervention compared with a bypass,
especially considering the economic costs of perioperative compli-
cations associated with each approach. However, as multiple inter-
ventions are performed this cost adds up and may ultimately prove
to be very expensive. Like most available studies on these emerging
technologies, ours is a retrospective analysis of a prospective data-
base and this methodology brings with it certain biases. All of these
modalities need to be further assessed in a prospective randomized
fashion in the future.
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